Rogers, Kerry A.
Mousa, Luay
Zhao, Qiuhong
Bhat, Seema A.
Byrd, John C.
El Boghdadly, Zeinab
Guerrero, Tomas
Levine, Lauren B.
Lucas, Fabienne
Shindiapina, Polina
Sigmund, Audrey M.
Sullivan, Matthew
Wiczer, Tracy E.
Woyach, Jennifer A.
Awan, Farrukh T.
Article History
Received: 11 December 2018
Revised: 12 March 2019
Accepted: 28 March 2019
First Online: 13 May 2019
Compliance with ethical standards
:
: The authors have the following disclosures: KAR received research funding from Genentech and consults for Acerta Pharma. SAB is on a speakers’ bureau for Janssen and Pharmacyclics. JCB receives research funding from Genentech, Acerta Pharma, Pharmacyclics, and Janssen. JAW received honoraria from Janssen, has consulted for Janssen, and receives research funding from MorphoSys, Karyopharm Therapeutics, and AbbVie. FTA has consulted for AbbVie, Gilead Sciences, AstraZeneca, Sunesis, Genentech, and Janssen, served on the speakers’ bureau for Abbvie and AstraZeneca, and received research funding from Pharmacyclics. LM, QZ, TEW, ZEB, TG, LBL, FL, PS, AS, and MS declare that they have no conflict of interest.